jueves, 19 de junio de 2014

Ahead of Print -New Insights from the 7th World Melioidosis Congress 2013 - Volume 20, Number 7—July 2014 - Emerging Infectious Disease journal - CDC

Ahead of Print -New Insights from the 7th World Melioidosis Congress 2013 - Volume 20, Number 7—July 2014 - Emerging Infectious Disease journal - CDC

Volume 20, Number 7—July 2014

Conference Summary

New Insights from the 7th World Melioidosis Congress 2013

Herbert P. SchweizerComments to Author , Direk Limmathurotsakul, and Sharon J. Peacock
Author affiliations: Colorado State University, Fort Collins, Colorado, USA (H.P. Schweizer)Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand (D. Limmathurotsakul)University of Cambridge, Cambridge, UK (S.J. Peacock)
Burkholderia pseudomallei and the disease that it causes, melioidosis, have gained increasing attention over the last decade, largely because of the biothreat agenda. The increased attention has led to a boost in research funding and invigorated research efforts worldwide. The 7th World Melioidosis Congress 2013 (WMC2013), held in Bangkok, Thailand, on September 18–20, 2013, was attended by 321 delegates from 24 countries and featured 73 oral presentations and 157 poster presentations. The Congress documented impressive progress in regard to fundamental biological questions and the emerging distribution, epidemiology, clinical management, and prevention of melioidosis; selected key findings are shown in the Figure.
WMC2013 delegates highlighted current challenges for the melioidosis research community. The 2 most pressing clinical needs are to reduce the global incidence of melioidosis and improve the clinical outcome of infected persons. A 2-pronged approach will likely be needed to reduce incidence: vaccine development plus prevention of infection through behavior modification to reduce exposure-prone activities (e.g., farming without protective clothing and drinking untreated water). Challenges to the development of an effective vaccine include achieving sterilizing immunity, protecting from multiple routes of infection (i.e., ingestion, inhalation, and inoculation), and invoking an immune response to an opportunistic disease in persons with risk factors for infection (15). Such issues were addressed during a session devoted to vaccine development. It is clear that much research remains to be done before a viable melioidosis vaccine candidate emerges.
B. pseudomallei is an environmental saprophyte, and infection occurs through ingestion, inhalation, or inoculation of the organism (16); lowering the exposure risk should reduce disease incidence. Our understanding of the global distribution of environmental B. pseudomallei is incomplete, although several WMC2013 presentations confirmed that the pathogen is more widespread in tropical and subtropical regions of the world than previously thought; new endemic foci have been reported in multiple regions of Africa and Puerto Rico. The increasing detection of this pathogen in the environment emphasizes the ongoing need for a working group tasked with assessing inexpensive and simple methods for the detection of environmental B. pseudomallei. Such a group has already established consensus guidelines on environmental sampling of B. pseudomallei (2) and on an updated global distribution map (http://www.melioidosis.info/map.aspx). B. pseudomallei habitat studies in diverse environments in northern Australia are contributing to this work, as is a B. pseudomallei whole-genome sequencing project of several hundred isolates, both of which will provide an accurate picture of bacterial phylogeography.
The mapping of human and animal melioidosis cases is also essential to the development and implementation of control measures. The number of countries reporting endemic melioidosis continues to expand, and the number of melioidosis cases reported worldwide continues to increase. The reasons for these increases are probably multifactorial and include rising disease awareness among physicians, improved diagnostic capabilities, and increasing numbers of persons with risk factors. A major risk factor for melioidosis is diabetes (16). The numbers of persons with diabetes are increasing in many countries, causing concern that melioidosis may become even more prevalent. New models that predict the global distribution and incidence of melioidosis were described at WMC2013; these models will contribute to more accurate prevalence estimates.
Improved outcome from melioidosis requires awareness, rapid diagnosis, and appropriate antimicrobial drug therapy. The lack of disease awareness among the public remains a major challenge, even in some countries with a high prevalence of disease. For example, Thailand is a major hotspot for melioidosis, yet public awareness of the disease is low. A survey of >4,200 persons in Thailand showed that only 26% had heard of melioidosis, and only 7% of those respondents knew what melioidosis is. There is an obvious need for risk communication, including education about daily activities that pose an exposure risk (10).
Diagnosing melioidosis is challenging because clinical signs of the disease are nonspecific and varied, and a definitive diagnosis depends on the availability of diagnostic microbiology facilities. Advances are being made in developing and implementing novel diagnostic methods, such as antigen-based diagnostic tests for the detection of B. pseudomallei in body fluids and culture media. WMC2013 attendees also reiterated the importance of resource sharing of diagnostic reagents, including a latex agglutination test for the identification of B. pseudomallei isolated from culture media. This test is simple and suitable for resource-poor settings, yet is not widely available (17).
Continued efforts are also required to improve melioidosis treatment, including the streamlining of initial intravenous antimicrobial drug therapy and subsequent oral drug therapies and new drug evaluations. The publication of a study that confirms that doxycycline is not required for the oral phase of melioidosis treatment with trimethoprim-sulfamethoxazole (3) was an important step toward improving treatment. There was also discussion about the possibility of reducing the duration of oral therapy if preceded by more prolonged intravenous antimicrobial drug therapy. Current melioidosis therapeutic options are largely limited to β-lactam drugs (e.g., ceftazidime and meropenem) and trimethoprim-sulfamethoxazole (4). Antimicrobial drugs developed for other gram-negative bacteria are being evaluated for in vitro and in vivo efficacy in animal models, but none are currently being considered for clinical trials in persons with melioidosis. Other WMC2013 presentations described the basis for clinically significant antimicrobial drug–resistance mechanisms (7) and the evaluation of novel drug targets.
Our rapidly improving understanding of the biology and pathogenesis of B. pseudomallei underpins the clinical aspirations for prevention, diagnosis, and improved patient outcome. As in other disciplines, whole-genome sequencing is being used in this field to ascertain pathogen evolution and adaptation to the host environment in chronically infected patients, such as persons with cystic fibrosis and non–cystic fibrosis bronchiectasis (18). The collective findings of numerous studies are unraveling host–pathogen interactions and the role of innate immunity during initial infection. Together with findings from studies of comparative B. pseudomallei gene expression in humans and murine hosts, such findings are becoming more clinically relevant. The report of various diabetic mouse models and their use for studying the pathogenesis of melioidosis reflects the significance of diabetes as a risk factor and our lack of knowledge in this area.
Notable progress was described at WMC2013 in basic and applied research concerning melioidosis and its bacterial cause, yet many challenges remain. Continued progress will undoubtedly be presented at the next WMC, scheduled for 2016 in Honolulu, Hawaii, USA.


We thank the conference organizers and all speakers and participants.


  1. Katangwe TPurcell JBar-Zeev NDenis BMontgomery JAlaerts MHuman melioidosis, Malawi, 2011. Emerg Infect Dis2013;19:9814 .DOIPubMed
  2. Limmathurotsakul DDance DAWuthiekanun VKaestli MMayo MWarner JSystematic review and consensus guidelines for environmental sampling of Burkholderia pseudomallei. PLoS Negl Trop Dis2013;7:e2105DOIPubMed
  3. Chetchotisakd PChierakul WChaowagul VAnunnatsiri SPhimda KMootsikapun PTrimethoprim-sulfamethoxazole versus trimethoprim-sulfamethoxazole plus doxycycline as oral eradicative treatment for melioidosis (MERTH): a multicentre, double-blind, non-inferiority, randomised controlled trial. Lancet2014;383:80714DOIPubMed
  4. Lipsitz RGarges SAurigemma RBaccam PBlaney DDCheng ACWorkshop on treatment of and postexposure prophylaxis for Burkholderia pseudomallei and B. mallei infection, 2010. Emerg Infect Dis2012;18:e2DOIPubMed
  5. Kager LMWiersinga WJRoelofs JJStroo IAchouiti Avan’t Veer CMice lacking the lectin-like domain of thrombomodulin are protected against melioidosis. Crit Care Med2014;42:e22130DOIPubMed
  6. Hodgson KAGovan BLWalduck AKKetheesan NMorris JLImpaired early cytokine responses at the site of infection in a murine model of type 2 diabetes and melioidosis comorbidity. Infect Immun2013;81:4707DOIPubMed
  7. Schweizer HPMechanisms of antibiotic resistance in Burkholderia pseudomallei: implications for treatment of melioidosis. Future Microbiol.2012;7:138999DOIPubMed
  8. Podnecky NLWuthiekanun VPeacock SJSchweizer HPThe BpeEF-OprC efflux pump is responsible for widespread trimethoprim resistance in clinical and environmental Burkholderia pseudomallei isolates. Antimicrob Agents Chemother2013;57:43816DOIPubMed
  9. Gallagher LARamage EPatrapuvich RWeiss EBrittnacher MManoil CSequence-defined transposon mutant library of Burkholderia thailandensis. MBio2013;4:e0060413DOIPubMed
  10. Limmathurotsakul DKanoksil MWuthiekanun VKitphati RdeStavola BDay NPActivities of daily living associated with acquisition of melioidosis in northeast Thailand: a matched case-control study. PLoS Negl Trop Dis2013;7:e2072DOIPubMed
  11. Limmathurotsakul DWongsuvan GAanensen DNgamwilai SSaiprom NRongkard PMelioidosis caused by Burkholderia pseudomallei in drinking water, Thailand, 2012. Emerg Infect Dis2014;20:2658DOIPubMed
  12. Mayo MKaesti MHarrington GCheng ACWard LKarp DBurkholderia pseudomallei in unchlorinated domestic bore water, Tropical Northern Australia. Emerg Infect Dis2011;17:12835DOIPubMed
  13. McRobb EKaestli MMayo MPrice EPSarovich DSGodoy DMelioidosis from contaminated bore water and successful UV sterilization. Am J Trop Med Hyg2013;89:3678DOIPubMed
  14. Scott AELaws TRD’Elia RVStokes MGNandi TWilliamson EDProtection against experimental melioidosis following immunization with liveBurkholderia thailandensis expressing a manno-heptose capsule. Clin Vaccine Immunol2013;20:10417DOIPubMed
  15. Peacock SJLimmathurotsakul DLubell YKoh GCWhite LJDay NPMelioidosis vaccines: a systematic review and appraisal of the potential to exploit biodefense vaccines for public health purposes. PLoS Negl Trop Dis2012;6:e1488DOIPubMed
  16. Wiersinga WJCurrie BJPeacock SJMelioidosis. N Engl J Med2012;367:103544DOIPubMed
  17. Amornchai PChierakul WWuthiekanun VMahakhunkijcharoen YPhetsouvanh RCurrie BJAccuracy of Burkholderia pseudomalleiidentification using the API 20NE system and a latex agglutination test. J Clin Microbiol2007;45:37746DOIPubMed
  18. Price EPSarovich DSMayo MTuanyok ADrees KPKaestli MWithin-host evolution of Burkholderia pseudomallei over a twelve-year chronic carriage infection. MBio2013;4:e0038813 . DOIPubMed
Suggested citation for this article: Schweizer HP, Limmathurotsakul D, Peacock SJ. New insights from the 7th World Melioidosis Congress 2013. Emerg Infect Dis. 2014 Jul [date cited]. http://dx.doi.org/10.3201/eid2007.131737

DOI: 10.3201/eid2007.131737

No hay comentarios:

Publicar un comentario